Posted by Michael Wonder on 31 May 2017
Drug makers brace for Trump's proposals to tackle U.S. prices
31 May 2017 - Novartis, Allergan CEOs foresee action in coming months.
Two top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
Novartis Chief Executive Officer Joe Jimenez and Allergan CEO Brent Saunders say that they anticipate proposals from the Trump administration anywhere within the next few weeks to the next few months. U.S. Health and Human Services Secretary Tom Price has been meeting with pharmacists, care providers and pharmacy-benefit managers in recent weeks to discuss ideas for making drugs more affordable.
